Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma

Authors

  • AL Kabir Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • MJ Rahman Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • M Begum Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • TF Dipta Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • MN Baqui Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • A Aziz Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • F Rahman Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • RC Debnath Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka
  • MA Habib Department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka

Keywords:

Antineoplastic combined chemotherapy

Abstract

Mymensingh Med J. 2012 Jan;21(1):114-119

The abstract of this article is available on the PubMed website

Abstract
370

Published

2012-11-08

How to Cite

Kabir, A., Rahman, M., Begum, M., Dipta, T., Baqui, M., Aziz, A., Rahman, F., Debnath, R., & Habib, M. (2012). Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. Mymensingh Medical Journal, 21(1), 114-119. https://doi.org/10.3329/mmj.v21i1.12522

Issue

Vol. 21 No. 1 (2012)

Section

Original Contributions

How to Cite

Kabir, A., Rahman, M., Begum, M., Dipta, T., Baqui, M., Aziz, A., Rahman, F., Debnath, R., & Habib, M. (2012). Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. Mymensingh Medical Journal, 21(1), 114-119. https://doi.org/10.3329/mmj.v21i1.12522